Dicronis
Z├╝rich
About Dicronis
Dicronis strive to enhance the quality-of-life of patients with their innovative technology. The first product in their pipeline, Lymphit, measures patient’s lymphatic function in a safe, home-based and highly scalable manner. The initial indication of Lymphit is the earliest possible diagnosis of secondary lymphedema, a serious side effect of many cancer therapies. By remotely monitoring the lymphatic function, the physician is enabled for the first time to perform an early diagnosis, before the swelling has occurred, and evaluate the best conservative treatment for the patient. This leads to a great improvement of the prognosis and quality of life of the patient and important savings for the healthcare system and society.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $291.8K
- Funding stage: Seed
- Last round: Pre-Seed (Jan 2019)
- Website: dicronis.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Life Science, Medical
Social Profiles
Canonical: https://fsome.com/organization/dicronis-178651 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.